Skip to content

Reference · Updated 10 November 2026

GLP-1 Drug Index

The GLP-1 Drug Index lists every GLP-1 medicine for weight loss that is approved or in late-stage trials, with who makes it, how it is taken, where it stands with regulators and its main trial result.

13GLP-1 drugs6FDA-approved1approved in China only3under review or Phase 3 done3in Phase 32related amylin drugs

Top 3 on the GLP-1 Performance Index

Weight loss per unit of side effects
See the full GLP-1 Performance Index →

GLP-1 receptor agonists

Drugs that act on the GLP-1 receptor alone. Semaglutide is the benchmark of the class, and orforglipron is the first non-peptide GLP-1 pill.

Semaglutide 2.4 mg

FDA approved

Wegovy · Novo Nordisk

Mechanism
GLP-1 receptor agonist
How it is taken
Injection, weekly
Approved
Jun 2021
Main trial
STEP 1, 2.4 mg weekly

The benchmark GLP-1 drug, with the longest real-world record and a proven reduction in heart attacks and strokes (SELECT trial).

Full Semaglutide 2.4 mg profile →

Semaglutide 7.2 mg

FDA approved

Wegovy HD · Novo Nordisk

Mechanism
GLP-1 receptor agonist
How it is taken
Injection, weekly
Approved
Mar 19, 2026
Main trial
STEP UP, 7.2 mg weekly

A triple-strength dose of Wegovy. More weight loss than the 2.4 mg dose, but altered skin sensations were reported by about 1 in 5 people.

Full Semaglutide 7.2 mg profile →

Wegovy pill · Novo Nordisk

Mechanism
GLP-1 receptor agonist
How it is taken
Oral, daily
Approved
Dec 22, 2025
Main trial
OASIS 4, 25 mg daily

The Wegovy molecule in a daily tablet, matching the injection's weight loss. Must be taken fasting with a sip of water and a 30-minute wait.

Full Oral semaglutide 25 mg profile →

Orforglipron

FDA approved

Foundayo · Eli Lilly

Mechanism
Non-peptide GLP-1 agonist
How it is taken
Oral, daily
Approved
Apr 1, 2026
Main trial
ATTAIN-1, 36 mg daily (sold as 17.2 mg tablet)

The first small-molecule GLP-1 pill: no food, water or timing rules. The trade-off is the least weight loss and the highest quit rate among approved options.

Full Orforglipron profile →

Liraglutide 3.0 mg

FDA approved

Saxenda · Novo Nordisk

Mechanism
GLP-1 receptor agonist
How it is taken
Injection, daily
Approved
Dec 2014
Main trial
SCALE Obesity and Prediabetes, 3.0 mg daily

The first-generation daily GLP-1 injection. Included as the historical baseline that newer drugs are measured against; it is not part of the rankings.

Full Liraglutide 3.0 mg profile →

GIP and GLP-1 drugs

Drugs that act on both GLP-1 and GIP, a second gut hormone. Tirzepatide and VK2735 activate both receptors; MariTide activates GLP-1 but blocks GIP.

Tirzepatide

FDA approved

Zepbound / Mounjaro · Eli Lilly

Mechanism
GIP/GLP-1 dual agonist
How it is taken
Injection, weekly
Approved
Nov 2023
Main trial
SURMOUNT-1, 15 mg weekly

The strongest approved option on weight and the gentlest on the stomach of any drug with full Phase 3 data. Acts on two gut hormones, GLP-1 and GIP.

Full Tirzepatide profile →

VK2735

In Phase 3

Viking Therapeutics

Mechanism
GIP/GLP-1 dual agonist
How it is taken
Injection (oral in development), weekly
Status
In Phase 3
Main trial
VENTURE, Up to 15 mg weekly

A tirzepatide-like dual agonist from an independent biotech. 14.7% weight loss in just 13 weeks. Phase 3 VANQUISH trials are fully enrolled, 78 weeks long.

Full VK2735 profile →

MariTide

In Phase 3

Maridebart cafraglutide · Amgen

Mechanism
GLP-1 agonist + GIP receptor blocker (antibody)
How it is taken
Injection, monthly
Status
In Phase 3
Main trial
Phase 2, Up to 420 mg monthly

A once-a-month injection that blocks GIP rather than activating it. Weight loss had not plateaued at one year.

Full MariTide profile →

GLP-1 and glucagon drugs

Drugs that add glucagon, which raises energy use and clears liver fat. Retatrutide also acts on GIP, making it a triple agonist.

Retatrutide

Phase 3 complete

Eli Lilly

Mechanism
GIP/GLP-1/glucagon triple agonist
How it is taken
Injection, weekly
Status
Phase 3 complete
Main trial
TRIUMPH-1, 12 mg weekly

The largest weight loss ever recorded in a major obesity trial. Side effects, including an unusual skin sensitivity, are also the highest. US filing planned for Q1 2027.

Full Retatrutide profile →

Mazdutide

Approved in China

Approved in China · Innovent / Eli Lilly

Mechanism
GLP-1/glucagon dual agonist
How it is taken
Injection, weekly
Approved
Jun 2025 (China)
Main trial
GLORY-1, 6 mg weekly

The world's first approved GLP-1/glucagon drug, licensed in China. Not available in the US or Europe.

Full Mazdutide profile →

Survodutide

Phase 3 complete

Boehringer Ingelheim / Zealand

Mechanism
GLP-1/glucagon dual agonist
How it is taken
Injection, weekly
Status
Phase 3 complete
Main trial
SYNCHRONIZE-1, 3.6 mg or 6 mg weekly

Strong liver-fat reduction, but roughly 1 in 4 people stopped treatment because of side effects, far above other drugs in this class.

Full Survodutide profile →

Amylin and GLP-1 combinations

Drugs that pair GLP-1 with amylin, a hormone released with insulin that signals fullness.

CagriSema

Under FDA review

Novo Nordisk

Mechanism
Amylin + GLP-1 combination
How it is taken
Injection, weekly
Status
Under FDA review
Main trial
REDEFINE 1, 2.4 mg cagrilintide + 2.4 mg semaglutide

Semaglutide plus cagrilintide, a long-acting amylin. Would be the first amylin-based obesity medicine. FDA decision expected in Q4 2026.

Full CagriSema profile →

Amycretin

In Phase 3

Novo Nordisk

Mechanism
Amylin/GLP-1 unimolecular agonist
How it is taken
Injection or oral, weekly
Status
In Phase 3
Main trial
Phase 1b/2a, 20 mg weekly

One molecule that activates both amylin and GLP-1 receptors. Early results showed about 22% weight loss at 36 weeks with no plateau.

Full Amycretin profile →

Want them ranked? The GLP-1 Performance Index scores each drug on weight loss per unit of side effects, and Compare puts any three side by side.

GLP-1 Drug Index: common questions

What is the GLP-1 Drug Index?

The GLP-1 Drug Index is a reference list of every GLP-1-based medicine for weight loss that is approved or in late-stage trials, maintained by Peptide Analysis. For each drug it shows the maker, mechanism, how it is taken, its regulatory status and its main trial result. It was last updated on 10 November 2026.

How many GLP-1 drugs are FDA-approved for weight loss?

Six GLP-1-based products are FDA-approved for weight management: Semaglutide 2.4 mg, Semaglutide 7.2 mg, Oral semaglutide 25 mg, Orforglipron, Liraglutide 3.0 mg and Tirzepatide. Mazdutide is approved in China only, and three more (Retatrutide, Survodutide and CagriSema) are under FDA review or have finished Phase 3.

Which GLP-1 drugs come as a pill?

Two approved GLP-1 medicines are taken by mouth: Oral semaglutide 25 mg and Orforglipron. Oral versions of VK2735 and Amycretin are also in development.

What is the difference between GLP-1, dual and triple agonists?

A GLP-1 agonist such as semaglutide acts on one gut hormone receptor. Dual agonists add a second target: tirzepatide adds GIP, while mazdutide and survodutide add glucagon. Retatrutide is a triple agonist that acts on GLP-1, GIP and glucagon. Adding targets has generally produced more weight loss, sometimes with more side effects.

Who makes GLP-1 drugs?

Most GLP-1 medicines come from two companies: six in this index are from Novo Nordisk and four involve Eli Lilly. Others are developed by Amgen, Boehringer Ingelheim with Zealand Pharma, Innovent and Viking Therapeutics.

Where can I see GLP-1 drugs ranked?

This index is a reference list and does not rank drugs. To see them ranked, the GLP-1 Performance Index scores each medicine on how much weight it takes off for each unit of side effects.

“Main trial” is the study behind each drug’s headline results, with the highest dose tested. The top 3 box is taken from the GLP-1 Performance Index. General information, not medical advice. Data as of 10 November 2026.